

Curriculum Vitae

MOJTABA FARJAM, MD-PHD

Personal Information:

Surname: Farjam

Given name: Mojtaba

E-mails: mfarjam@fums.ac.ir,
farjam.md@gmail.com

Address: Noncommunicable Disease Research Center, Fasa University of Medical Sciences, Fasa, Iran. Postal Code: ۷۴۶۱۶۸۶۶۸۸

Tel: +۹۸۷۱۵۳۳۱۴۰۶۸

Education:

- Doctorate of Philosophy in medical pharmacology (PhD), ۲۰۱۳
Department of pharmacology, Shiraz University of Medical Sciences, Shiraz, Iran
- Research Scholar in Neuroimmune Pharmacology of Multiple Sclerosis, ۲۰۱۲
Hospital for neurosciences, Thomas Jefferson University, Philadelphia, PA, USA
- Doctorate of Medicine (MD), ۲۰۰۱
Fasa University of Medical Sciences, Fasa, Iran

Employment:

- Associate Professor of medical and clinical pharmacology, Fasa University of Medical Sciences, Fasa, Iran (۲۰۱۹-present)
- Vice chancellor of research and technology, Fasa University of Medical Sciences, Fasa, Iran (۲۰۱۶-۲۰۲۲)
- Vice chancellor of Health, Fasa University of Medical Sciences, Fasa, Iran (۲۰۱۴-۲۰۱۵)
- Dean of Clinical Education, Fasa University of Medical Sciences, Fasa, Iran (۲۰۱۳-۲۰۱۴)
- Assistant Professor of medical and clinical pharmacology, Fasa University of Medical Sciences, (۲۰۱۳-۲۰۱۹)
- Manager of the R&D office of a research-based pharmaceutical holding company, Jahan Behbood Corporation, Tehran, Iran (۲۰۰۳-۲۰۰۹).
- Manager and founder of the R&D office of Fars Pharmacists' Association (۲۰۰۱- ۲۰۰۳)
- CCU and Cardiology emergency ward practitioner in Alzahra Cardiology Centre: staff physician (۲۰۰۱-۲۰۰۳).

Honors & Awards:

- Outstanding researcher award, Fasa University of Medical Sciences, Fasa, Iran (۲۰۲۰)
- Outstanding researcher award, Fasa University of Medical Sciences, Fasa, Iran (۲۰۱۴)

Organizing, Outreach, & Committee Services:

- Non-communicable Disease Congress chair, Fasa University of Medical Sciences, Fasa, Iran (Feb ۲۰۱۹)
- Start-up Weekend at Fasa University of Medical Sciences, Fasa, Iran (March ۲۰۱۸)
- Non-communicable Disease Congress chair, Fasa University of Medical Sciences, Fasa, Iran (Aug. ۲۰۱۶)
- Consultant of Fars Multiple Sclerosis (MS) support Charity NGO. (۲۰۱۱-Present)
- Co-Chair of ۳rd World Cancer Congress Track ۴-۳: Neuro-Oncological Cancer Drug Discovery, Singapore ۲۰۱۰

Grants:**- National Grants:**

۱. NIMAD (National Institute for Medical Research Development) grant on Stem Cell Research (۲۰۱۶)
۲. Supporting Grant for Fasa-Persian Cohort study (۲۰۱۵)
۳. Supporting Grant for Fasa-Youth Cohort study (۲۰۱۵)

- University Grants:

۱. Correlation between happiness and depression based on Oxford Happiness and Beck Depression Inventory among students of Fasa University of Medical Sciences (Grant No: ۹۳۰۱۷)
۲. Comparison of the relationship between sleep quality and happiness among students of Fasa University of Medical Sciences (Grant No: ۹۳۰۴۴)
۳. The evaluation of socio-economic inequalities of gastroesophageal reflux disease using concentration index (Grant No: ۹۳۰۲۷)

٤. The healing effect of Cupressus Semperviren on histopathological changes and oxidative stress in colons of ulcerative colitis-induced rats (Grant No: ٩٥٠٦٢)
٥. The healing effect of Shark Liver Oil on histopathological changes and oxidative stress in colons of ulcerative colitis-induced rats (Grant No: ٩٥٠٨٣)
٦. Prevalence of smoking and opium and their correlation with Lipid Profile levels in rural population: the Fasa cohort study (Grant No: ٩٤١٥٣)
٧. Evaluation the therapeutic effect of hydroalcoholic extract of equisetum Arvense L. on ٥-fluorouracil induced- oral mucositis in golden hamster (Grant No: ٩٦٠٦٥)
٨. A pharmacoepidemiologic study of prescriptions in Fasa in the first nine months of ١٣٩٥ (Grant No: ٩٥٢٤١)
٩. evaluation of early outcome in patients with STEMI and thrombotic lesions under treatment with half therapeutic dose of Heparin and Integrilin and compare with full therapeutic dose of heparin during ppci (Grant No: ٩٥٢٠٦)
١٠. The prevalence of mood disorders and substance abuse in parents of children with Attention Deficit – Hyperactivity (Grant No: ٩٥١٩٦)
١١. Defining BMI Cutoff According to Body Composition Fat Percent in Fasa Cohort study (Grant No: ٩٧٠١٦)
١٢. evaluation of convulsion and ECG characteristics in electroconvulsive therapy after duloxetine treatment in mice (Grant No: ٩٦١٧٧)
١٣. Study of type ٢ diabetics and their related factors in diabetic population investigated in Fasa Cohort study (Grant No: ٩٦٢٤٤)
١٤. Investigating the use of antidepressants and anti-dementia drugs and antiepileptic drugs on the quantity and quality of sleep in Sheshdeh, Fasa (Grant No: ٩٦٢٣٤)
١٥. Evaluation of Socioeconomic Status on Non-Communicable Diseases: A Population- Based Survey from Fasa Cohort Study, Southern Iran (Grant No: ٩٦٢١٢)
١٦. To study causative link between Autophagy defects and Tauopathy employing iPS Cells-derived neurons from Alzheimer's patients (Grant No: ٩٧٠٠٥)

۱۷. Correlation between Body composition and Electrocardiographic characteristic in Fasa cohort study (Grant No: ۹۷۰۴۸)
۱۸. Investigating the effects of oral administration of assa foetida on the brain, liver, kidneys, and gonads of mice and determination of its mean lethal dose (ld₅₀) (Grant No: ۹۷۱۰۸)
۱۹. The relation between obesity and low socioeconomic status in Fasa Cohort population (Grant No: ۹۷۰۹۶)
۲۰. comparison of sleep duration between subjects with cardiovascular diseases and healthy subjects (Grant No: ۹۷۱۷۴)
۲۱. Gene expression analysis of GAD¹ & GAD² in rats with Psychophysiological Insomnia (Grant No: ۹۷۰۳۲)
۲۲. Correlation between Apolipoprotein A¹ level and insulin level and Framingham cardiometabolic risk factors in population of Persian cohort of Fasa (Grant No: ۹۷۱۹۶)
۲۳. Comparison of characteristics, prognosis and outcome of acute MI in opium dependent patients and non-dependents. A case-control study (Grant No: ۹۷۲۹۳)
۲۴. Spatial Analysis of Persons Covered by the Persian Fasa Cohort with ۱۰-Year Risk of Cardiovascular Disease Based on the Framingham Scoring System Using GIS Mapping System (Grant No: ۹۷۴۰۰)
۲۵. Investigation of Prevalence of hypertension and its relation with cardiovascular risk factors in the Cohort Persian Fasa (Grant No: ۹۷۳۴۵)
۲۶. Assessing of ECG change in patient with drugs that act in the central nervous system in fasa Cohort center (Grant No: ۹۷۱۶۵)
۲۷. The best QT correction formula for the Iranian population (Grant No: ۹۷۴۴۹)
۲۸. A Capsule Network-based Framework for early Identification of COVID-۱۹ cases from chest computed tomography Images (Grant No: ۹۹۰۳۰)

Presentations:

١. The Association of Electrocardiogram Parameters and Abnormalities with Predicted Risk of Cardiovascular diseases Among an Iranian Rural Population: The Fasa PERSIAN Cohort Study. The International Student Congress of (bio)Medical Sciences (ISCOMS). Groningen, Netherlands, ٢٠٢٢
٢. Upper Body Fat Mass was Related with Prolonged Corrected QT Interval on the Electrocardiogram in Men: The Fasa PERSIAN Cohort Study. Presented at the Digital International Student Congress of (bio)Medical Sciences. Netherlands, ٢٠٢٠
٣. Insufficient Heart Rate Control by Beta-blockers in Coronary Artery Disease Subjects: A population Pharmacology Study from The Fasa PERSIAN Cohort Study. Presented at the ٣rd Euro-Asian Pharmacoepidemiology Congress. Isfahan, Iran, ٢٠٢٢
٤. Nutritional Starvation induces Tau hyperphosphorylation via disrupting autophagy-lysosomal pathway. The ٤th USERN Congress and Prize Awarding Festival. Budapest, Hungary, ٢٠١٩
٥. Comparison of Anthropometrics and Body Composition Data Between Two Groups of Sufficient and Insufficient Sleep Presented at the ٢٠th Annual Research Congress of Iranian Medical Students. Kermanshah, Iran, ٢٠١٩
٦. Geriatric Health Data Base Project in Fasa University of Medical Sciences: A First Step toward Promotion of the Health and the Quality of Lives of the Iranian Senior Citizens in the Society. Health congress, Shiraz, ٢٠١٣
٧. Inhibition of NR٢B-containing N-methyl-D-aspartate receptors (NMDARs) for Neuroprotection in Experimental Autoimmune Encephalomyelitis. ١٠th MS congress, Isfahan, Iran, ٢٠١٣

۸. Levels of Prevention of Multiple Sclerosis: Evidence- Based Hypotheses. ۱۰th MS congress, Isfahan, Iran, ۲۰۱۳
۹. The Effect of *Ro ۲۵-۶۹۸۱* (an Antagonist of NR۲B-Containing NMDA Receptor) on Neurological Damage and Calpain and Caspase ۳ Activities in Experimental Model of Multiple Sclerosis. ۱۰th MS congress, Isfahan, Iran, ۲۰۱۳
۱۰. Psychoneuroimmunology and Neuroimmune Pharmacology, Shiraz University of Medical Sciences, pharmacology departmental seminar, ۲۰۱۱
۱۱. Hepatic Encephalopathy, Basic to Clinical. Shiraz University of Medical Sciences, pharmacology departmental seminar, ۲۰۱۱
۱۲. Calpain, Molecule in Focus. Shiraz University of Medical Sciences, basic science hall, ۲۰۱۰
۱۳. Cell Death Cascades and apoptosis in Acute Hepatic Encephalopathy. Hepatogastrointestinal research Center, Shiraz University of Medical Sciences, the Conference Hall of the University President, Feb ۲۰۱۰.
۱۴. Tumor hypoxia and anti-tumor bioreductive agents. ۳rd World Cancer Congress, Singapore, ۲۰۱۰
۱۵. Clinical trials in drug development, Kavar Applied Sciences University, ۲۰۰۹
۱۶. Research and development in chemopharmaceutical industry. Comprehensive University of Science and Practice of Kavar, ۲۰۰۹
۱۷. Curcumin and burn, Shiraz medical school, pharmacology departmental seminar, ۲۰۰۹
۱۸. Genetic Aspects of response to antidepressants and toxicogenetics. Shiraz medical school, pharmacology departmental seminar, ۲۰۰۸
۱۹. Cancer chemotherapeutics. Shiraz University of Medical Sciences, pharmacology chemotherapy seminar, ۲۰۰۸
۲۰. Pseudomembranous colitis. A text review. Shiraz University of Medical Sciences, pharmacology chemotherapy seminar, ۲۰۰۸

- ۲۱. Pharmacotherapy in patients with renal and hepatic failure, Shiraz University of Medical Sciences, Clinical pharmacology seminar, ۲۰۰۸
- ۲۲. Dermato-pharmacology, Shiraz medical school, Clinical pharmacology seminar, ۲۰۰۸
- ۲۳. Intracellular calcium in astrocytes. Shiraz medical school, pharmacology neuroscience seminar, ۲۰۰۷
- ۲۴. Flavin containing monooxygenase (FMO) in drug metabolism and development. Shiraz medical school, pharmacology departmental seminar, ۲۰۰۷

Publications:

- ۱. Salehi Z, **Farjam M**, Hashempur MH. Case Reports in Traditional and Integrative Medicine. *Traditional and Integrative Medicine*. ۲۰۲۲ Sep ۰.
- ۲. Roshan A, Heidari Sarvestani M, Moradi Z, Dehghan A, **Farjam M**. Comparison of Sleep Quantity in Patients with Chronic Diseases: Results from a Population-Based Study. *Sleep and Vigilance*. ۲۰۲۲ Aug ۲۲:۱-۶.
- ۳. Habibzadeh A, Lankarani KB, **Farjam M**, Akbari M, Kashani SM, Karimimoghadam Z, Wang K, Imanieh MH, Tabrizi R, Ahmadizar F. Prevalence of Fungal Drug Resistance in COVID-۱۹ Infection: a Global Meta-analysis. *Current fungal infection reports*. ۲۰۲۲ Aug ۱۰:۱-۱.
- ۴. Amini M, Moradinazar M, Rajati F, Soofi M, Sepanlou SG, Poustchi H, Eghtesad S, Moosazadeh M, Harooni J, ..., **Farjam M**, ..., Aghazadeh-Attari J, Fallahi M. Socioeconomic inequalities in prevalence, awareness, treatment and control of hypertension: evidence from the PERSIAN cohort study. *BMC Public Health*. ۲۰۲۲ Dec;۲۲(۱):۱-۱.
- ۵. Jamshidi A, **Farjam M**, Ekramzadeh M, Homayounfar R. Evaluating type and amount of dietary protein in relation to metabolic syndrome among Iranian adults: cross-sectional

analysis of Fasa Persian cohort study. *Diabetology & Metabolic Syndrome*. ۲۰۲۲ Dec;۱۴(۱):۱-۶.

۶. Yazdanpanah MH, Naghizadeh MM, Sayyadipoor S, **Farjam M**. The best QT correction formula in a non-hospitalized population: the Fasa PERSIAN cohort study. *BMC cardiovascular disorders*. ۲۰۲۲ Dec;۲۲(۱):۱-۲.
۷. **Farjam M**, Dehghan A, Bijani M, Salimi S, Bahramali E, Alkamel A. Investigating the Complications and Consequences of Myocardial Infarction between Abusers and Non-abusers of Opiate: A Cross-sectional Study in the South of Iran. *Asia Pacific Journal of Medical Toxicology*. ۲۰۲۲ Jun ۱۹;۱۱(۲):۴۶-۵۰.
۸. Kazeminejad Z, Marzi M, Shiroudi A, Kouhpayeh SA, **Farjam M**, Zarenezhad E. Novel ۱, ۲, ۴-Triazoles as Antifungal Agents. *BioMed Research International*. ۲۰۲۲ Mar ۲۲;۲۰۲۲.
۹. Zamani M, Poustchi H, Shayanrad A, Pourfarzi F, **Farjam M**, Noemani K, Ghaderi E, Mohammadkarimi V, Kahnooji M, Mansour-Ghanaei F, Rastegar A. Prevalence and determinants of anemia among Iranian population aged ≥ 30 years: A PERSIAN cohort-based cross-sectional study. *PLoS one*. ۲۰۲۲ Feb ۹;۱۷(۲):e۰۲۶۳۷۹۰.
۱۰. Zareei S, Behrasi F, Naghizadeh MM, Talebzadeh F, Kharmandar A, Davoodi SH, Asadi M, **Farjam M**, Homayounfar R. Oral contraceptive pill and metabolic syndrome: Fasa Persian Cohort Study (Descriptive study). *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. ۲۰۲۲ Feb ۱;۱۶(۲):۱۰۲۴۰۸.
۱۱. Marzi M, **Farjam M**, Kazeminejad Z, Shiroudi A, Kouhpayeh A, Zarenezhad E. A Recent Overview of ۱, ۲, ۳-Triazole-Containing Hybrids as Novel Antifungal Agents: Focusing on Synthesis, Mechanism of Action, and Structure-Activity Relationship (SAR). *Journal of Chemistry*. ۲۰۲۲ Jan ۶;۲۰۲۲.
۱۲. Mohammadi F, Tehranineshat B, **Farjam M**, Rahnavard S, Bijani M. The Correlation between Resilience, Self-efficacy and Illness Perception in Patients with Type ۲ Diabetes: A Cross-Sectional Study. *Clinical Diabetology*. ۲۰۲۲;۱۱(۳):۱۷۰-۸۲.
۱۳. Golshani SA, Zohalinezhad ME, Amoozegar F, **Farjam M**. Spanish Flu in Tehran from ۱۹۱۸ to ۱۹۲۰. *Archives of Iranian Medicine*. ۲۰۲۲ Jan ۱;۲۰(۱):۷۱-۵.
۱۴. Eghbal B, Hekmat AS, Kouhpayeh SA, Ghanbariasad A, Javanmardi K, Samimi N, Fakhræi, B., **Farjam, M**. Evaluating the Effect of Electroconvulsive Shock and Duloxetine Combination Therapy on Behavioral, Cardiovascular, and Brain Oxidative Stress Markers in the Rats. *Galen Medical Journal*. ۲۰۲۱;۱۰:e۲۲۱۸-e.
۱۵. Askari M, Askari Z, Zarei Z, **Farjam M**, Homayounfar R. Prevalence of general and abdominal obesity and its relationship with opium, total opiate drugs, and chronic

smoking: Fasa cohort study. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. ۲۰۲۲;۱۶(۱):۱۰۲۳-۳۵۷.

۱۶. Marzi M, **Farjam M**, Kazeminejad Z, Shiroudi A, Kouhpayeh A, Zarenezhad E. A Recent Overview of ۱, ۲, ۳-Triazole-Containing Hybrids as Novel Antifungal Agents: Focusing on Synthesis, Mechanism of Action, and Structure-Activity Relationship (SAR). *Journal of Chemistry*. ۲۰۲۲;۲۰۲۲.
۱۷. Zareei S, Behrasi F, Naghizadeh MM, Talebzadeh F, Kharmandar A, Davoodi SH, ..., **Farjam, M**. Oral contraceptive pill and metabolic syndrome: Fasa Persian Cohort Study (Descriptive study). *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. ۲۰۲۲;۱۰۲۴-۰۸.
۱۸. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, ..., **Farjam M**. Worldwide trends in hypertension prevalence and progress in treatment and control from ۱۹۹۰ to ۲۰۱۹: a pooled analysis of ۱۲۰۱ population-representative studies with ۱.۴ million participants. *The Lancet*. ۲۰۲۱;۳۹۸(۱۰۳۰۴):۹۵۷-۸۰.
۱۹. Zendejboudi T, Afshar AR, Khoradmehr A, Azari H, **Farjam M**, Tamadon A. Marine Biobank: From Protection of Genetic Resources to Biomedical Entrepreneurship. *ISMJ*. ۲۰۲۱;۲۴(۴):۲۴۲-۶۴.
۲۰. Zarenezhad E, **Farjam M**, Iraj A. Synthesis and biological activity of pyrimidines-containing hybrids: Focusing on pharmacological application. *Journal of Molecular Structure*. ۲۰۲۱;۱۲۳۰:۱۲۹۸۳۳.
۲۱. Zarenezhad E, Behrouz S, **Farjam M**, Rad MS. A Mini Review on Discovery and Synthesis of Remdesivir as an Effective and Promising Drug against COVID-۱۹. *Russian Journal of Bioorganic Chemistry*. ۲۰۲۱;۴۷(۳):۶۰۹-۲۱.
۲۲. Zahmatkeshan M, Zakerabasali S, **Farjam M**, Gholampour Y, Seraji M, Yazdani A. The use of mobile health interventions for gestational diabetes mellitus: a descriptive literature review. *Journal of Medicine and Life*. ۲۰۲۱;۱۴(۲):۱۳۱.
۲۳. Yazdanpanah MH, **Farjam M**, Naghizadeh MM, Jedi F, Mohebi K, Homayounfar R. Sleep duration and anthropometric indices in an Iranian population: the Fasa PERSIAN cohort study. *Scientific reports*. ۲۰۲۱;۱۱(۱):۱-۱۰.
۲۴. Yazdanpanah MH, Bahramali E, Naghizadeh MM, **Farjam M**, Mobasheri M, Dadvand S. Different body parts' fat mass and corrected QT interval on the electrocardiogram: The Fasa PERSIAN Cohort Study. *BMC cardiovascular disorders*. ۲۰۲۱;۲۱(۱):۱-۱۱.
۲۵. Yazdanpanah MH, Bahramali E, Kazemi M, Firouzabadi N, Arasteh P, Homayounfar R, ..., **Farjam M**, ... The Fasa Registry on Systolic Heart Failure (FaRSH): Feasibility Study and the First ۵-year Reports. *Galen Medical Journal*. ۲۰۲۱;۱۰:e۲۱۱۱-e.

۲۶. Soltani Hekmat A, **Farjam M**, Javanmardi K, Behrouz S, Zarenezhad E, Soltani Rad MN. Design, Synthesis and In Vivo Cardiovascular Evaluation of Some Novel Aryloxy Propanol Amino Acid Derivatives. *ChemistrySelect*. ۲۰۲۱;۶(۴۷):۱۳۵۹۵-۶۰۰.
۲۷. Siervo M, Rubele S, Shannon OM, Prado CM, Donini LM, Zamboni M, ..., **Farjam M**, ... Prevalence of sarcopenic obesity and association with metabolic syndrome in an adult Iranian cohort: The Fasa PERSIAN cohort study. *Clinical Obesity*. ۲۰۲۱:e۱۲۴۵۹.
۲۸. Sharafi M, Bahramali E, **Farjam M**, Rezaeian S, Afrashteh S, Amiri Z. Socioeconomic inequality in noncommunicable diseases: Results from a baseline Persian cohort study. *Medical Journal of the Islamic Republic of Iran*. ۲۰۲۱;۳۵:۷۸.
۲۹. Samimi N, Sharma G, Kimura T, Matsubara T, Huo A, Chiba K, ..., **Farjam M**, ... Distinct phosphorylation profiles of tau in brains of patients with different tauopathies. *Neurobiology of Aging*. ۲۰۲۱;۱۰۸:۷۲-۹.
۳۰. Samimi N, **Farjam M**, Klionsky DJ, Rezaei N. The role of autophagy in the pathogenesis of SARS-CoV-۲ infection in different cell types. *Autophagy*. ۲۰۲۱:۱-۴.
۳۱. Samieefar N, Boroujeni RY, Jamee M, Lotfi M, Golabchi MR, Afshar A, ..., **Farjam M**, ... Country quarantine during COVID-۱۹: critical or not? *Disaster medicine and public health preparedness*. ۲۰۲۱;۱۵(۴):e۲۴-e۵.
۳۲. Dehghan A, Heidari Z, Karimi J, Jafarnejhad A, Atef S, Sharifi H, ..., **Farjam M**. Validity and reliability of Persian version of quality of life questionnaire in people living with HIV/AIDS (WHOQOL-HIV-BREF). *AIDS*. ۳۶:۲۷,۹.
۳۳. Samangoeei M, **Farjam M**, Niknam Z, Etemadifar M, hasan Meshkibaf M, Noroozi S. Evaluation of matrix metalloproteinase-۹ plasma levels in untreated new Relapsing–remitting multiple sclerosis patients and their first-degree family. *Metabolic Brain Disease*. ۲۰۲۱:۱-۶.
۳۴. Rajabi A, Shojaei A, Janani L, Farjam M, Baradaran HR, Khosravi P, ..., **Farjam M**, ... Cigarette Smoking Behavior a Gateway to Opium Use Disorder: A Mendelian Randomization Analysis. *Behavior Genetics*. ۲۰۲۱:۱-۹.
۳۵. Pezeshki B, Karimi A, Ansari A, Yazdanpanah MH, Elmi M, **Farjam M**, et al. Fasa Registry on Diabetes Mellitus (FaRD): Feasibility Study and Pilot Phase Results. *Galen Medical Journal*. ۲۰۲۱;۱۰:e۲۱۳۷-e.
۳۶. Motamedi A, Ekramzadeh M, Bahramali E, **Farjam M**, Homayounfar R. Diet quality in relation to the risk of hypertension among Iranian adults: cross-sectional analysis of Fasa PERSIAN cohort study. *Nutrition Journal*. ۲۰۲۱;۲۰(۱):۱-۱۰.

۳۷. Mohammadi F, **Farjam M**, Gholampour Y, Sohrabpour M, Oshvandi K, Bijani M. Caregivers' perception of the caring challenges in coronavirus crisis (COVID-۱۹): a qualitative study. *BMC nursing*. ۲۰۲۱;۲۰(۱):۱-۹.
۳۸. Mirahmadizadeh A, **Farjam M**, Sharafi M, Fatemian H, Kazemi M, Geraylow KR, et al. The relationship between demographic features, anthropometric parameters, sleep hours, and physical activity and ECG parameters in Fasa Persian cohort study. ۲۰۲۱.
۳۹. Kazemi M, Bazyar M, Naghizadeh MM, Dehghan A, Rahimabadi MS, Chijan MR, ..., **Farjam M**, ... Lipid profile dysregulation in opium users based on Fasa PERSIAN cohort study results. *Scientific reports*. ۲۰۲۱;۱۱(۱):۱-۹.
۴۰. Collaboration NRF including **Farjam M**. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight. *Elife*. ۲۰۲۱;۱۰:e۶۰۰۶۰.
۴۱. Bastami M, Masotti A, Saadatian Z, Daraei A, **Farjam M**, Ghanbariasad A, et al. Critical roles of microRNA-۱۹۶ in normal physiology and non-malignant diseases: Diagnostic and therapeutic implications. *Experimental and Molecular Pathology*. ۲۰۲۱;۱۰:۴۶۶۴.
۴۲. Askari M, Askari Z, Zarei Z, **Farjam M**, Homayounfar R. Prevalence of general and abdominal obesity and its relationship with opium, total opiate drugs, and chronic smoking: Fasa cohort study. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. ۲۰۲۱;۱۰:۲۳۰۷.
۴۳. Alipanah H, **Farjam M**, Zarenezhad E, Roozitalab G, Osanloo M. Chitosan nanoparticles containing limonene and limonene-rich essential oils: potential phytotherapy agents for the treatment of melanoma and breast cancers. *BMC Complementary Medicine and Therapies*. ۲۰۲۱;۲۱(۱):۱-۱۰.
۴۴. Zarghami A, **Farjam M**, Fakhraei B, Hashemzadeh K, Yazdanpanah MH. A report of the telepsychiatric evaluation of SARS-CoV-۲ patients. *Telemedicine and e-Health*. ۲۰۲۰;۲۶(۱۲):۱۴۶۱-۵.
۴۵. Yazdanpanah MH, Sayyadipoor S, Hojati SR, Nikmanesh A, **Farjam M**, Homayounfar R. The association of metabolic syndrome and its components with electrocardiogram parameters and abnormalities among an Iranian rural population: the Fasa PERSIAN Cohort Study. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. ۲۰۲۰;۱۳:۲۹۷۵.
۴۶. Yazdanpanah MH, Homayounfar R, Khademi A, Zarei F, Shahidi A, **Farjam M**. Short sleep is associated with higher prevalence and increased predicted risk of cardiovascular diseases in an Iranian population: Fasa PERSIAN Cohort Study. *Scientific reports*. ۲۰۲۰;۱۰(۱):۱-۱۳.

٤٧. Taddei C, Zhou B, Bixby H, Carrillo-Larco RM, Jackson RT, Farzadfar F, ..., **Farjam M**, ... Repositioning of the global epicentre of non-optimal cholesterol. *Nature*. ٢٠٢٠;٥٨٢:٧٣-٧.
٤٨. Samimi N, Sepehrimanesh M, Koochi-Hosseiniabadi O, Homayounfar R, Mokhtari M, **Farjam M**. The therapeutic effect of shark liver oil in a rat model of acetic acid-induced ulcerative colitis. *Evidence-Based Complementary and Alternative Medicine*. ٢٠٢٠;٢٠٢٠.
٤٩. NCD Risk Factor Collaboration Group Including **Farjam M**. Height and body-mass index trajectories of school-aged children and adolescents from ١٩٨٥ to ٢٠١٩ in ٢٠٠ countries and territories: a pooled analysis of ٢١٨١ population-based studies with ٦٥ million participants. *Lancet London: Elsevier*, ٢٠٢٠, vol ٣٩٦, no ١٠٢٦١. ٢٠٢٠.
٥٠. Zarenezhad E, **Farjam M**, Iraj A. Synthesis and Biological Activity of Pyrimidines-Containing Hybrids: Focusing on Pharmacological Application. *Journal of Molecular Structure*. ٢٠٢١:١٢٩٨٣٣.
٥١. NCD Risk Factor Collaboration Group Including **Farjam M**. Repositioning of the global epicenter of non-optimal cholesterol. *Nature*. ٢٠٢٠;٥٨٢:٧٣-٧.
٥٢. Moradinazar M, Najafi F, Jalilian F, Pashar Y, Hamzeh B, Shakiba E, et al. Prevalence of drug use, alcohol consumption, cigarette smoking and measure of socioeconomic-related inequalities of drug use among Iranian people: findings from a national survey. *Substance Abuse Treatment, Prevention, and Policy*. ٢٠٢٠;١٥:١-١١.
٥٣. Zarghami A, **Farjam M**, Fakhraei B, Hashemzadeh K, Yazdanpanah MH. A Report of the Telepsychiatric Evaluation of SARS-CoV-٢ Patients. *Telemedicine and e-Health*. ٢٠٢٠.
٥٤. Yazdanpanah MH, Homayounfar R, Khademi A, Zarei F, Shahidi A, **Farjam M**. Short sleep is associated with higher prevalence and increased predicted risk of cardiovascular diseases in an Iranian population: Fasa Persian Cohort Study. *Scientific reports*. ٢٠٢٠;١٠(١):١-١٣.
٥٥. Pezeshki B, Golrazeghi M, Hojati SR, Rostamian F, Raeisi Shahraki H, **Farjam M**, et al. Comparison of Formulas for Low-Density Lipoprotein (LDL) Calculation for Predicting the Risk of Metabolic Syndrome. *Galen Medical Journal*. ٢٠٢٠;٩:١٦٠٧.

۵۶. Samimi N, **Farjam M**. The Effect of Cupressus Sempervirens on Ulcerative Colitis: Do Pathological Changes Improve by Oxidative Stress Amelioration? Galen Medical Journal. ۲۰۱۹;۸:۱۶۵۰.
۵۷. Afsarian MH, **Farjam M**, Zarenezhad E, Behrouz S, Rad MNS. Synthesis, Antifungal Evaluation and Molecular Docking Studies of Some Tetrazole Derivatives. Acta Chimica Slovenica. ۲۰۱۹;۶۶(۴):۸۷۴-۸۷.
۵۸. Karyani AK, Matin BK, Soltani S, Rezaei S, Soofi M, Salimi Y, et al. Socioeconomic gradient in physical activity: findings from the PERSIAN cohort study. BMC public health. ۲۰۱۹;۱۹(۱):۱۳۱۲.
۵۹. Hashemi M, Dadkhah P, Taheri M, Ghasemi M, Hosseinpoor A, **Farjam M**. Patient-Reported Outcomes and Satisfaction after Cervical Epidural Steroid Injection for Cervical Radiculopathy. Galen Medical Journal. ۲۰۱۹;۸:۱۴۷۸.
۶۰. Rajabi A, Khosravi P, Motevalian SA, **Farjam M**, Shojaei A. The association between polymorphism of the BDNF gene and cigarette smoking in the Iranian population. The journal of gene medicine. ۲۰۱۸;۲۰(۱۰-۱۱):e۳۰۵۲.
۶۱. Sepehrimanesh M, Samimi N, Koohi-Hosseinabadi O, Mokhtari M, Amiri-Zadeh S, **Farjam M**. Effects of Cupressus sempervirens extract on the healing of acetic acid-induced ulcerative colitis in rat. Journal of Coloproctology (Rio de Janeiro). ۲۰۱۸;۳۸(۴):۳۰۹-۱۳.
۶۲. **Farjam M**, Sharafi M, Bahramali E, Rezaei S, Hassanzadeh J, Rezaeian S. Socioeconomic inequalities in gastroesophageal reflux disorder: results from an Iranian cohort study. Middle East journal of digestive diseases. ۲۰۱۸;۱۰(۳):۱۸۰.
۶۳. Zarenezhad E, Rad MNS, Behrouz S, Esmailzadeh S, **Farjam M**. Immobilized [Cu(cdsalMeen)] on silica gel: a highly efficient heterogeneous catalyst for 'Click'[۳+ ۲] Huisgen cycloaddition. Journal of the Iranian Chemical Society. ۲۰۱۷;۱۴(۲):۵۰۹-۱۹.
۶۴. Zarandi FBaB, Geramizadeh B, **Farjam M**, Farjadian S, Alizadeh A. Correlation Between Neurological Deficits and Spinal Cord Pathological Changes in a Mouse Model of Multiple Sclerosis. Iranian Journal of Science and Technology, Transactions A: Science. ۲۰۱۷;۴۱(۴):۸۶۷-۷۱.

٦٥. Hekmat AS, Javanmardi K, Kouhpayeh A, Baharamali E, **Farjam M**. Differences in cardiovascular responses to alamandine in two-kidney, one clip hypertensive and normotensive rats. *Circulation Journal*. ٢٠١٧;٨١(٣):٤٠٥-١٢.
٦٦. Shabrang B, Jamshidzadeh A, **Farjam M**, Ebrahimpour A, Koochi-Hosseiniabadi O. Concurrent assessment of calpain and caspase-٣ activities in brains of mice with acetaminophen-induced acute hepatic encephalopathy. *Metabolic Brain Disease*. ٢٠١٧;٣٢(٦):٢١٣٩-٤٢.
٦٧. Eghtesad S, Mohammadi Z, Shayanrad A, Faramarzi E, Joukar F, Hamzeh B, et al. The PERSIAN cohort: providing the evidence needed for healthcare reform. *Archives of Iranian medicine*. ٢٠١٧;٢٠(١١):٦٩١-٥.
٦٨. Askari A, Ehrampoush E, Homayounfar R, Bahramali E, **Farjam M**. Serum insulin in pathogenesis and treatment of osteoarthritis. *Medical hypotheses*. ٢٠١٧;٩٩:٤٥-٦.
٦٩. Nadim M, **Farjam M**. Qutb al-Dīn Shīrāzī (١٢٣٦-١٣١١), Persian polymath physician in the medieval period. *Journal of medical biography*. ٢٠١٦;٢٤(٣):٣٦٠-٢.
٧٠. **Farjam M**, Bahrami H, Bahramali E, Jamshidi J, Askari A, Zakeri H, et al. A cohort study protocol to analyze the predisposing factors to common chronic non-communicable diseases in rural areas: Fasa Cohort Study. *BMC Public Health*. ٢٠١٦;١٦(١):١-٨.
٧١. Bahramali E, Askari A, Zakeri H, **Farjam M**, Dehghan A, Zendejdel K. Fasa Registry on Acute Myocardial Infarction (FaRMI): feasibility study and pilot phase results. *PloS one*. ٢٠١٦;١١(١٢):e٠١٦٧٥٧٩.
٧٢. Askari A, Gholami T, NaghiZadeh MM, **Farjam M**, Kouhpayeh SA, Shahabfard Z. Hyaluronic acid compared with corticosteroid injections for the treatment of osteoarthritis of the knee: a randomized control trail. *Springerplus*. ٢٠١٦;٥(١):٤٤٢.
٧٣. Ashkani-Esfahani S, Bagheri F, Emami Y, Esmaeilzadeh E, Azarpira N, Hassanabadi N, et al. Protective effects of co-enzyme Q١٠ on thioacetamide-induced acute liver damage and its correlation with behavioral, biochemical, and pathological factors. *Iranian Red Crescent Medical Journal*. ٢٠١٦;١٨(٨).

٧٤. Zohalinezhad ME, Askari A, **Farjam M**. Clinical stories and medical histories recorded by Rhazes (٨٦٥-٩٢٥), the Iranian-Islamic physician in the medieval period. *AMHA-Acta medico-historica Adriatica*. ٢٠١٥;١٣:٧٧-٨٦.
٧٥. Mehrabani D, **Farjam M**, Geramizadeh B, Tanideh N, Amini M, Panjehshahin MR. The healing effect of curcumin on burn wounds in rat. *World journal of plastic surgery*. ٢٠١٥;٤(١):٢٩.
٧٦. **Farjam M**, Zhang G-X, Ciric B, Rostami A. Emerging immunopharmacological targets in multiple sclerosis. *Journal of the neurological sciences*. ٢٠١٥;٣٥٨(١-٢):٢٢-٣٠.
٧٧. **Farjam M**, Fakhraei B, Hosseinabadi O. Calpain in acute hepatic encephalopathy: a player in pathophysiology and a possible target for pharmacological intervention. *Prensa Med Argent*. ٢٠١٤;١٠٠(٧).
٧٨. Askari A, **Farjam M**, Zohalinezhad ME. Early reports of bone repair techniques and bone xenograft in Persian traditional medicine. *Journal of integrative medicine*. ٢٠١٥;١٣(٣):١٤٠-١.
٧٩. **Farjam M**, Zarandi FBaB, Farjadian S, Geramizadeh B, Nikseresht AR, Panjehshahin MR. Inhibition of NR٢B-containing N-methyl-D-aspartate receptors (NMDARs) in experimental autoimmune encephalomyelitis, a model of multiple sclerosis. *Iranian journal of pharmaceutical research: IJPR*. ٢٠١٤;١٣(٧):٦٩٥.
٨٠. Fakhraei B, **Farjam M**. Evidence-based hypotheses about levels of prevention of multiple sclerosis: current findings, future prospects. *La Prensa Medica Argentina*. ٢٠١٤;١٠٠(٣).
٨١. **Farjam M**, Ebrahimpour A, Fakhraei B. CD٢١ positive B cell: a novel target for treatment of multiple sclerosis. *Medical hypotheses*. ٢٠١٣;٨٠(٥):٥٥٦-٧.
٨٢. Farjadian S, Moghtaderi M, Fakhraei B, Nasiri M, **Farjam M**. Association between serotonin transporter gene polymorphisms and childhood asthma. *Journal of Asthma*. ٢٠١٣;٥٠(١٠):١٠٣١-٥.
٨٣. Esfahani SA, Esmaeilzadeh E, Bagheri F, Emami Y, **Farjam M**. The effect of co-enzyme q١٠ on acute liver damage in rats, a biochemical and pathological study. *Hepatitis monthly*. ٢٠١٣;١٣(٨).

^ξ. **Farjam M**, Dehdab P, Abbassnia F, Mehrabani D, Tanideh N, Pakbaz S, et al. Thioacetamide-induced acute hepatic encephalopathy in rat: behavioral, biochemical and histological changes. Iranian Red Crescent Medical Journal. ۲۰۱۲; ۱۴(۳): ۱۶۴.